Rahul Mohindar of Viratechindia proposed that the investors should hold Ranbaxy Laboratories as it may have a good 7-8% upside.

Mr. Mohindar said, “Pharma is suggesting more of a downside. On a medium to short-term basis one wouldn’t look at the sector positively especially going by the healthcare Index etc. But Ranbaxy Laboratories seems to be out performing that and maybe one have a good 7-8% upside in the stock but when we look at its peers the chart looks negative side. I don't think, it can do too much from here and once again this is a case where the risk reward, where the sector and all of these factors are not favoring a buy, so would venture out still at these levels.”

He also said that those interested in investing in Ranbaxy laboratories should wait for a moment. It’s time to make profit not investing. It’s better to invest when it returned to its lower price.

Ranbaxy Laboratories Limited is an incorporated, research based, global pharmaceutical company, developing a broad variety of quality, reasonable generic medicines. It is placed amongst the top ten international generic companies and has a occurrence in 23 of the top 25 pharmaceutical markets of the world. The company is headquartered in India. It has presence in 49 countries, with manufacturing facilities in 11 and a diverse product portfolio.